Key TakeawaysHealth Canada has granted conditional authorization for Eisai's (ESALY) LEQEMBI® (lecanemab), marking it as the first treatment in Canada to target the underlying cause of early Alzheimer's disease.U.S. pre-market futures are showing significant gains, with S&P 500 futures up 0.9% and Nasdaq-100 futures gaining 1.3%, fueled by optimism over a new framework for Trump-Xi trade talks this week.China's industrial profits have seen a notable rise, a development attributed to ongoing official crackdo ...